GLP-1 – SRK BHARAT

GLP-1 Medications Drive Surge in Revenue for Pharmaceutical Giants

Eli Lilly reported a remarkable 91 percent increase in second-quarter sales for its diabetes medication Mounjaro, reaching $9.94 billion and significantly surpassing Wall Street expectations. This extraordinary financial growth highlights…

srkanalytics.srk@gmail.com August 6, 2026

Health

BMJ Study Links Popular GLP-1 Diabetes and Weight-Loss Drugs to Higher Risk of Hair Loss

A new BMJ study links popular GLP-1 weight-loss and diabetes drugs to a higher risk of hair loss compared to other treatments.

srkanalytics.srk@gmail.com July 24, 2026

Health

Medicare Begins Coverage of GLP-1 Drugs for Weight Loss July 1: What to Know

Starting July 1, the federal government will initiate a restricted pilot program providing Medicare coverage for GLP-1 receptor agonists specifically for weight loss, marking a significant shift in how the…

srkanalytics.srk@gmail.com July 2, 2026

Business

Medicare Expands Coverage to Include GLP-1 Drugs for Weight Loss

New Policy Marks Shift in Medicare CoverageIn a significant policy shift, Medicare has announced it will now provide coverage for GLP-1 receptor agonists prescribed specifically for weight management, setting a…

srkanalytics.srk@gmail.com June 30, 2026

Health

GLP-1 Weight Loss Drugs Linked to Reduced Physical Activity, Study Finds

A recent observational study has revealed that individuals prescribed GLP-1 receptor agonists—a class of drugs including Ozempic, Wegovy, and Mounjaro—exhibit a measurable decline in physical activity levels shortly after beginning…

srkanalytics.srk@gmail.com June 29, 2026

Health

Health Canada Approves Zepbound for Sleep Apnea in Adults with Obesity, Marking a New Chapter in Treatment

Discover how Health Canada's approval of Zepbound offers a groundbreaking new treatment for sleep apnea in adults with obesity.

srkanalytics.srk@gmail.com June 26, 2026